Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sara Ekelund"'
Publikováno v:
British Journal of Pharmacology. 137:568-573
The present study was aimed at elucidating the apoptosis inhibitory properties of the cyanoguanidine CHS 828. CHS 828 exhibits impressive cytotoxic activity in vitro and in vivo. Apoptosis is not its main mode of cytotoxic effect, and we have previou
Publikováno v:
Biochemical Pharmacology. 63:1491-1498
The role of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) and the ADP-ribosylation inhibitor 3-aminobenzamide (3-ABA) in the cytotoxicity induced by the novel antitumoral cyanoguanidine CHS 828 was investigated in the human lymphoma cell line
Publikováno v:
Anti-Cancer Drugs. 9:531-538
Microphysiometry is a non-invasive, physiological method where measurement of metabolic activity can be made on living human tumor cells. Indirect measurement of the extracellular acidification is measured over a pH-sensitive silicon membrane. In thi
Publikováno v:
Chemotherapy. 48(4)
Background: CHS 828 is a novel cyanoguanidine with cytotoxic properties which was recently shown to induce an early increase in extracellular acidification. This could hypothetically be exploited for combination with drugs interfering with, or being
Publikováno v:
Anticancer research. 22(4)
N-(6-(4-chlorophenoxy)hexyl)-N'-cyano-N''-4-pyridylguanidine, CHS 828, is a new anti-neoplastic agent with promising anti-tumor activity both in vitro and in vivo. To characterize the metabolic events over time, the lymphoma cell line U-937 GTB was e
Publikováno v:
European journal of pharmacology. 418(1-2)
N-(6-(4-chlorophenoxy)hexyl)-N'-cyano-N"-4-pyridylguanidine (CHS 828) is a new guanidino-containing compound with antitumoral activity both in vitro and in vivo. Its activity profile differs from those of standard cytotoxic drugs but the mechanism of
Autor:
Gunnar Liminga, Rolf Larsson, Lise Binderup, Charlotte Schou, Erik Rytter Ottosen, Fredrik Björkling, Sara Ekelund
Publikováno v:
Biochemical pharmacology. 60(6)
CHS 828, a newly recognized pyridyl cyanoguanidine, has shown promising antitumor activity both in vitro and in vivo and is presently in early phase I clinical trial in collaboration with EORTC. In this study, the effects of CHS 828 and a series of a